Skip to main content
. 2022 Feb 25;2022:6324292. doi: 10.1155/2022/6324292

Figure 4.

Figure 4

GLB as a potential sensitizer for cisplatin in human ovarian cancer cells. (a, b) A2780 or A2780/DDP cells were treated with GLB or cisplatin alone or their combination for 24 h; the cell viability was determined by trypan blue exclusion. (c, d) Combination index (CI) values were calculated using the Chou-Talalay method. (e, f) A2780 or A2780/DDP cells were treated with GLB or cisplatin alone or their combination; the colony formation ability was measured by colony-forming assay. Data from three technical replicates (∗∗∗p < 0.001).